Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-02T19:05:59.345Z.
Calculation as of: 2026-10-02T19:05:59.345Z.
Quote observation: 2026-10-02T19:05:17.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: a42e17afc1a1b5c0c05c4bcc318afc1e85bdb01f5d7a677422ba224d703768eb
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Recursion Pharmaceuticals, Inc.
Market Cap
$2.13B
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.74B
EV/EBITDA Ratio
4.46x
TTM Avg
6.97x
3Y Avg
36.61x
5Y Avg
27.69x
Market Cap
$1.71B
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.72B
EV/EBITDA Ratio
26.38x
TTM Avg
36.07x
3Y Avg
85.76x
5Y Avg
85.76x
Market Cap
$1.01B
EV/EBITDA Ratio
12.47x
TTM Avg
29.31x
3Y Avg
194.51x
5Y Avg
194.51x
Market Cap
$470.35M
EV/EBITDA Ratio
N/A
TTM Avg
74.72x
3Y Avg
37.71x
5Y Avg
26.88x
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Recursion Pharmaceuticals, Inc. (RXRX) | $2.13B | N/A | N/A | N/A | N/A |
| Beam Therapeutics Inc. (BEAM)vs › | $2.49B | N/A | N/A | N/A | N/A |
| DENTSPLY SIRONA Inc. (XRAY)vs › | $1.74B | 4.46x | 6.97x | 36.61x | 27.69x |
| Intellia Therapeutics, Inc. (NTLA)vs › | $1.71B | N/A | N/A | N/A | N/A |
| TransMedics Group, Inc. (TMDX)vs › | $2.72B | 26.38x | 36.07x | 85.76x | 85.76x |
| Teladoc Health, Inc. (TDOC)vs › | $1.01B | 12.47x | 29.31x | 194.51x | 194.51x |
| NeoGenomics, Inc. (NEO)vs › | $470.35M | N/A | 74.72x | 37.71x | 26.88x |
| NRC Health (NRC)vs › | $459.30M | 23.37x | 16.26x | 15.04x | 16.68x |
| Shoulder Innovations, Inc. (SI)vs › | $389.98M | N/A | N/A | N/A | N/A |
| PDS Biotechnology Corporation (PDSB)vs › | $41.24M | N/A | N/A | N/A | N/A |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
